Skip to search formSkip to main contentSkip to account menu

0.6 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe [Arixtra]

Known as: FONDAPARINUX SODIUM 7.5 mg in 0.6 mL SUBCUTANEOUS INJECTION, SOLUTION [ARIXTRA], 0.6 ML Arixtra 12.5 MG/ML Prefilled Syringe, Arixtra 7.5 MG in 0.6 ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

6 relations
ArixtraFondaparinux sodiumPrefilled SyringeSodium Chloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Advancing MSn spatial resolution and documentation for glycosaminoglycans by sulfate-isotope exchange
Glycosaminoglycans (GAGs) are carbohydrate polyionic polymers that participate in a host of critically important biological… 
2015
2015
Investigating changes in the gas-phase conformation of Antithrombin III upon binding of Arixtra using traveling wave ion mobility spectrometry (TWIMS).
We validate the utility of ion mobility to measure protein conformational changes induced by the binding of glycosaminoglycan… 
2012
2012
A closer look at the nitrogen next door: 1H-15N NMR methods for glycosaminoglycan structural characterization.
Review
2012
Review
2012
Fondaparinux Sodium
SummaryAbstractFondaparinux sodium (Arixtra®; fondaparinux) is the first of a new class of synthetic pentasaccharide… 
2009
2009
An Ion Mobility-Mass Spectrometry Investigation of Monocyte Chemoattractant Protein-1.
Review
2008
Review
2008
Fondaparinux Sodium
SummaryAbstractFondaparinux sodium (Arixtra®) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is… 
2004
2004
Le pentasaccharide (fondaparinux sodium, Arixtra ® ) : avantage à la synthèse ?
Auteur(s) :, Roger Cariou* Departement therapeutique thrombose, Sanofi Synthelabo Recherche, 91385 Chilly Mazarin cedex, France… 
2004
2004
Initial Outpatient Treatment of Venous Thromboembolism with Fondaparinux (Arixtra®): The Matisse Trials.
Background: The MATISSE trials showed that a single dose regimen of fondaparinux, a synthetic selective factor Xa inhibitor, was… 
2002
2002
FONDAPARINUX (ARIXTRA®): A NEW ANTICOAGULANT
Fondaparinux is a promising new antithrombotic agent. This pentasaccharide selectively and specifically inhibits coagulation… 
2002
2002
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
Fondaparinux (Arixtra®; Sanofi-Synthélabo/Organon) is the first of a new class of antithrombotic agents distinct from low… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)